Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05977998

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Sponsor: M.D. Anderson Cancer Center

Conditions Carcinomatosis Gastric Adenocarcinoma

Interventions Dexamethasone Diphenhydramine Famotidine Paclitaxel

Updated 10 times since 2023 Last updated: Nov 18, 2025 Started: Sep 8, 2023 Primary completion: Oct 31, 2028 Completion: Oct 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinomatosis and Gastric Adenocarcinoma and is currently actively recruiting participants. M.D. Anderson Cancer Center leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE2
Jul 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Mar 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States